Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | IDO1 | P14902 | 6/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | ACLY | P53396 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13799438 | 0.90 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2C9MAPK1CYP2C19 | |
| SCHEMBL1648141 | 0.87 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2C9MAPK1CYP2C19 | |
| SCHEMBL11621292 | 0.84 | IDO1 (0.65) | CYP1A2CYP3A4CYP2C9MAPK1CYP2C19 | |
| SCHEMBL14534844 | 0.83 | CYP1A2 (0.53) | CYP1A2CYP3A4CYP2C9MAPK1CYP2C19 | |
| SCHEMBL4863737 | 0.77 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2C9MAPK1CYP2C19 | |
| SCHEMBL7020135 | 0.77 | IDO1 (0.58) | CYP1A2CYP3A4CYP2C9MAPK1CYP2C19 | |
| SCHEMBL29587149 | 0.77 | IDO1 (0.58) | CYP1A2CYP3A4CYP2C9MAPK1CYP2C19 | |
| SCHEMBL398220 | 0.76 | IDO1 (0.56) | CYP1A2CYP3A4CYP2C9MAPK1CYP2C19 | |
| SCHEMBL2766402 | 0.76 | IDO1 (0.56) | CYP1A2CYP3A4CYP2C9MAPK1CYP2C19 | |
| SCHEMBL1779915 | 0.76 | IDO1 (0.56) | CYP1A2CYP3A4CYP2C9MAPK1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060270649-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2006-11-30 | — | — | US | disclosed |
| US-6858603-B2 | Acetindine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| US-20040235816-A1 | Azetidine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2004-11-25 | — | — | US | disclosed |
| US-20030162808-A1 | Acetindine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2003-08-28 | — | — | US | disclosed |
| US-6518264-B2 | For treatment/prevention of psychoses, other brain disorders, and cardiovascular disorders | AVENTIS PHARMA S.A. (FR) | 2003-02-11 | — | — | US | disclosed |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2002-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235816-A1 | Azetidine derivatives, their preparation and medicaments containing them | AZI2, ADRA2A, ADRA2C | CYP1A2 26/4885CYP3A4 68/4885CYP2C9 31/4885 |
| US-20060270649-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | AZI2, QDPR, ADRA2A | CYP1A2 31/4885CYP3A4 71/4885CYP2C9 33/4885 |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | CYP11B2, AZI2, CYP2C19 | CYP1A2 8/4885CYP3A4 15/4885CYP2C9 10/4885 |
| US-20030162808-A1 | Acetindine derivatives, their preparation and medicaments containing them | ADRA1D, ADRB2, AZI2 | CYP1A2 14/4885CYP3A4 40/4885CYP2C9 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.